The effect of ketamine on premenstrual syndrome in women

The effect of ketamine on premenstrual syndrome in female employees of Zanjan University of Medical Sciences

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150825023760N9

Enrollment

Registered

2025-01-22

Start date

2025-01-25

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual syndrome. Premenstrual tension syndrome

Interventions

Intervention 1: Intervention group: Women with premenstrual syndrome will receive ketamine (manufactured by Rotex Medica, Germany, 50 mg/10 ml) intravenously at a dose of 0.25 mg/kg over 1 hour. Inter

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Women 18-45 years old American Society of Anesthesiologists Class I and II Mild to moderate menstrual distress (score less than 93 on the Moos Questionnaire) Having a regular menstrual cycle (at least 28 days)

Exclusion criteria

Exclusion criteria: History of psychiatric medication History of drug allergy Contraindications for ketamine (history of seizures, hypertension, tachycardia, cardiac ischemia, liver dysfunction)

Design outcomes

Primary

Measure	Time frame
Mean score of menstrual distress. Timepoint: Before and after the intervention. Method of measurement: Moos Menstrual Distress Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaramarz Heydari

Zanjan University of Medical Sciences

heydarifaramarz@yahoo.com+98 24 3313 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026